Monitoring individual response to brain-tumour chemotherapy: proton MR spectroscopy in a patient with recurrent glioma after stereotactic radiotherapy
- PMID: 14685797
- DOI: 10.1007/s00234-003-1116-8
Monitoring individual response to brain-tumour chemotherapy: proton MR spectroscopy in a patient with recurrent glioma after stereotactic radiotherapy
Abstract
Since antineoplastic activity varies, sensitive methods for individual assessment of efficacy are needed. We demonstrate the clinical value of MR spectroscopy in monitoring chemotherapy in a patient with recurrent glioma after stereotactic radiotherapy. Diagnostic imaging before and after chemotherapy included contrast-enhanced MRI, single-voxel proton MR spectroscopy ((1)H MRS), (1)H MR spectroscopic imaging ((1)H SI), and fluorodeoxyglucose (FDG) positron-emission tomography (PET). A significant decrease in choline signal intensity was observed 2 months after chemotherapy indicating tumour chemosensitivity, in line with tumour shrinkage on MRI and decreased uptake of FDG. Assessment of early response by MRS may help to improve treatment protocols in other patients.
Similar articles
-
Evaluation of the response of metastatic brain tumors to stereotactic radiosurgery by proton magnetic resonance spectroscopy, 201TlCl single-photon emission computerized tomography, and gadolinium-enhanced magnetic resonance imaging.J Neurosurg. 2004 May;100(5):835-41. doi: 10.3171/jns.2004.100.5.0835. J Neurosurg. 2004. PMID: 15137602
-
[Application of (1)H MR spectroscopic imaging in radiation oncology: choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors].Rofo. 2006 Jun;178(6):627-33. doi: 10.1055/s-2006-926744. Epub 2006 May 15. Rofo. 2006. PMID: 16703499 German.
-
Second-line treatment with carboplatin for recurrent or progressive oligodendroglial tumors after PCV (procarbazine, lomustine, and vincristine) chemotherapy: a phase II study.Cancer. 2004 Feb 15;100(4):807-13. doi: 10.1002/cncr.20042. Cancer. 2004. PMID: 14770438 Clinical Trial.
-
Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.Neurology. 2004 Aug 10;63(3):535-7. doi: 10.1212/01.wnl.0000133398.11870.9a. Neurology. 2004. PMID: 15304589 Review.
-
Chemotherapy for diffuse low-grade gliomas in adults.Rev Neurol (Paris). 2011 Oct;167(10):673-9. doi: 10.1016/j.neurol.2011.08.006. Epub 2011 Sep 8. Rev Neurol (Paris). 2011. PMID: 21906770 Review.
Cited by
-
The role of imaging in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.J Neurooncol. 2014 Jul;118(3):435-60. doi: 10.1007/s11060-013-1330-0. Epub 2014 Apr 9. J Neurooncol. 2014. PMID: 24715656
-
The Treatment of Malignant Gliomas.Curr Treat Options Neurol. 2005 Jul;7(4):293-303. doi: 10.1007/s11940-005-0039-6. Curr Treat Options Neurol. 2005. PMID: 15967092
-
Comments and controversies: magnetic resonance spectroscopy and gliomas.Cancer Imaging. 2006 Sep 7;6(1):113-5. doi: 10.1102/1470-7330.2006.0018. Cancer Imaging. 2006. PMID: 16966066 Free PMC article.
-
Imaging of brain tumors: MR spectroscopy and metabolic imaging.Neuroimaging Clin N Am. 2010 Aug;20(3):293-310. doi: 10.1016/j.nic.2010.04.003. Neuroimaging Clin N Am. 2010. PMID: 20708548 Free PMC article. Review.
-
Effects of flutamide on [methyl-(3)h]-choline uptake in human prostate cancer-3 cells: a pilot study.Curr Ther Res Clin Exp. 2007 Jul;68(4):226-41. doi: 10.1016/j.curtheres.2007.08.003. Curr Ther Res Clin Exp. 2007. PMID: 24683213 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical